Tony Tarragona

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity

Barry Peters, Walter Jaoko, Eftyhia Vardas et al. · Vaccine · 2006 · 109 citations

Vaccination, Vaccine Development, Immunology +6

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

Walter Jaoko, Frederick N. Nakwagala, Omu Anzala et al. · Vaccine · 2008 · 91 citations

Vaccination, Plasmid Pthr Dna, Vaccine Development +11

Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents

Mark Boaz, Peter Hayes, Tony Tarragona et al. · Clinical and Vaccine Immunology · 2008 · 60 citations · Full text

A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus

Eftyhia Vardas, Pontiano Kaleebu, Linda‐Gail Bekker et al. · AIDS Research and Human Retroviruses · 2010 · 48 citations

Immunology, Immunotherapy, Human Retrovirus +16

Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India.

Sanjay Mehendale, Seema Sahay, Madhuri Thakar et al. · PubMed · 2010 · 20 citations